The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 26, 2019
Filed:
Feb. 06, 2019
Applicant:
Dalhousie University, Halifax, Nova Scotia, CA;
Inventors:
Christopher McMaster, Halifax, CA;
Gordon Simms, Halifax, CA;
Assignee:
DALHOUSIE UNIVERSITY, Halifax, Nova Scotia, CA;
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07D 471/04 (2006.01); C07J 31/00 (2006.01); A61P 9/10 (2006.01); A61P 25/28 (2006.01); A61P 9/00 (2006.01); A61P 19/10 (2006.01); A61P 9/12 (2006.01); A61P 11/00 (2006.01); A61P 15/00 (2006.01); A61P 25/00 (2006.01); C07F 9/38 (2006.01); A61P 27/02 (2006.01); A61K 31/444 (2006.01); C07C 229/24 (2006.01); C07C 317/48 (2006.01); A61P 3/10 (2006.01); C07F 9/09 (2006.01); C07F 9/6558 (2006.01);
U.S. Cl.
CPC ...
C07D 471/04 (2013.01); A61K 31/444 (2013.01); A61P 3/10 (2018.01); A61P 9/00 (2018.01); A61P 9/10 (2018.01); A61P 9/12 (2018.01); A61P 11/00 (2018.01); A61P 15/00 (2018.01); A61P 19/10 (2018.01); A61P 25/00 (2018.01); A61P 25/28 (2018.01); A61P 27/02 (2018.01); C07C 229/24 (2013.01); C07C 317/48 (2013.01); C07F 9/3808 (2013.01); C07J 31/006 (2013.01); C07F 9/091 (2013.01); C07F 9/65583 (2013.01);
Abstract
Methods and compositions are provided for the treatment of familial exudative vitreoretinopathy (FEVR) through the administration of a therapeutically effective amount of a sphingosine-1-phosphate receptor type 2 (S1PR2) antagonist. Also provided herein are (Z)-3-((2,6-dichloropyridin-4-yl)amino)-3-(((4-isopropyl-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)methyl)amino)acrylonitrile and analogs thereof, and their use in treating retinopathies and diseases characterized by insufficient angiogenesis.